Analystreport

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com